Aldeyra Therapeutics (ALDX) Tops Q3 EPS by 5c

Aldeyra Therapeutics (NASDAQ: ALDX) reported Q3 EPS of ($0.32), $0.05 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Aldeyra Therapeutics (ALDX) click here.

You May Also Be Interested In

• BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• 'Long-term deals significant positive for stock:' Analysts react to Micron results